1. World Health Organization. Chronic obstructive pulmonary disease (COPD). Available at: 〈https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)〉 [Accessed July 2023].
2. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis;Adeloye;Lancet Respir. Med.,2022
3. Summary of opinion (initial authorisation). Eklira Genuair: aclidinium bromide. European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), EMA/CHMP/304272/2012, 24 May 2012, 〈https://www.ema.europa.eu/en/documents/smop-initial/chmp-positive-summary-opinion-eklira-genuair_en.pdf〉 [Accessed July 2023].
4. Approval Package for Tudorza Pressair (aclidinium bromide inhalation powder), U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Approval Date: 23 July 2012, 〈https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000Approv.pdf〉 [Accessed July 2023].
5. Summary of opinion (initial authorisation). Duaklir Genuair: aclidinium bromide/ formoterol fumarate dihydrate. European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), EMA/CHMP/490903/2014, 25 September 2014, 〈https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-duaklir-genuair_en.pdf〉 [Accessed July 2023].